Merck reports strong Q3 2026 revenue and Ontario vaccine inclusion

Merck has announced that Ontario will include its pneumococcal vaccine, CAPVAXIVE, in its publicly funded adult immunization program starting in 2026. Approved by Health Canada, the vaccine is intended for adults aged 18 and older to prevent invasive pneumococcal disease (IPD) caused by 21 Streptococcus pneumoniae serotypes.

Canadian surveillance data from 2019 to 2023 indicates that the serotypes covered by CAPVAXIVE accounted for approximately 65% of IPD cases in adults aged 18–49, 74% in adults aged 50–64, and 80% in adults aged 65 and older.

In its Q3 2026 financial results, Merck reported revenue of $18.09 billion, a 4.7% increase year-on-year, exceeding analyst estimates. The company raised its full-year revenue guidance to approximately $67.05 billion and increased its full-year adjusted earnings per share guidance to $2.80.